The enGenes team, led by CEO Dr. Juergen Mairhofer, will contribute to the Summit’s Intensified and Continuous Processing stream with a presentation demonstrating the impact of its iCAP platform on next-generation plasmid DNA manufacturing.
iCAP: Unlocking continuous bioprocessing
On the morning of day 3 (Thursday, March 12 at 11:40), Dr. Mairhofer will present in the session Unlocking Sustainable Bioprocessing on the topic: “Integrated Continuous and Automated Platform for Plasmid Production.”
His presentation will address how conventional batch production – often costly and yield-limited – constrains plasmid DNA’s growing role in enabling viral vectors, mRNA vaccines, and DNA therapeutics.
The proprietary iCAP platform developed by enGenes replaces traditional batch approaches with a fully integrated continuous and automated microbial process, combining bioprocess intensification with advanced digital intelligence.
Enabling stable bioreactor cascades
Dr. Mairhofer will outline how iCAP leverages genetically stabilized E. coli and a growth-decoupled replication system to enable stable, long-term plasmid production in bioreactor cascades.
Continuous alkaline lysis, chromatographic purification and real-time digital twin–based control together ensure high-throughput, low-variability plasmid recovery.
The presentation will demonstrate how iCAP sets a new benchmark for sustainable plasmid DNA biomanufacturing through modular, scalable processing that reduces production costs and environmental footprint, while supporting decentralized vaccine manufacturing and integrated therapeutic supply models.
Advanced, lower-cost solutions
In addition to its conference presentation, enGenes will participate in the Summit’s 1-on-1 partnering and networking program to highlight its latest enabling technologies, including:
- -eXrase™ – a next-generation recombinant endonuclease delivering efficient DNA/RNA digestion at significantly lower cost than conventional market alternatives
- -eXfinity™ – high-performance affinity ligands supporting efficient and selective purification of biotherapeutics from discovery through to large-scale manufacturing, also designed to reduce cost compared with traditional purification solutions
About enGenes Biotech
With more than a decade of proven expertise, enGenes Biotech develops bioprocesses that consistently outperform conventional approaches. The company’s proprietary technology platforms deliver higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli. These directly translate into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.
enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. It can deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position in the global marketplace.
The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.
Find out more at: https://www.engenes.cc
About BioProcess Summit Europe 2026
First held in 2017, the annual BioProcess Summit Europe focuses on advancing semi-continuous and fully continuous processing strategies in upstream (USP) and downstream processing (DSP) for clinical and commercial biomanufacturing.
The 8th BioProcess Summit Europe will take place from March 10–12 at the InterContinental Barcelona Hotel and Convention Center. The meeting will feature seven conference streams that include upstream and downstream processing, cell and gene therapy, peptides and oligonucleotides, intensified and continuous processing, and the impact of AI and digitalization.
The event is organised by Cambridge Healthtech Institute with further information at: https://www.bioprocessingeurope.com
Resources
See enGenes Plasmid DNA Services.
Learn more at enGenes high performance bioprocessing products.
Contact
enGenes Biotech GmbH
Address:Muthgasse 11/Stiege 2, 1. Stock, 1190 Vienna, Austria
Telephone No:+43 1 93 46 707-0
Email Address:office@engenes.cc
Web Address:http://www.engenes.cc